These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35457595)

  • 21. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Memantine in moderate-to-severe Alzheimer's disease.
    Reisberg B; Doody R; Stöffler A; Schmitt F; Ferris S; Möbius HJ;
    N Engl J Med; 2003 Apr; 348(14):1333-41. PubMed ID: 12672860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine.
    Gilling KE; Jatzke C; Parsons CG
    Neuropharmacology; 2007 Sep; 53(3):415-20. PubMed ID: 17632186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of Memantine and 6-Chlorotacrine as Novel Multi-Target Compound against Alzheimer's Disease.
    Kaniakova M; Nepovimova E; Kleteckova L; Skrenkova K; Holubova K; Chrienova Z; Hepnarova V; Kucera T; Kobrlova T; Vales K; Korabecny J; Soukup O; Horak M
    Curr Alzheimer Res; 2019; 16(9):821-833. PubMed ID: 30819076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Memantine in the treatment of mild-to-moderate Alzheimer's disease.
    Cosman KM; Boyle LL; Porsteinsson AP
    Expert Opin Pharmacother; 2007 Feb; 8(2):203-14. PubMed ID: 17257090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
    Farlow MR
    Geriatrics; 2004 Jun; 59(6):22-7. PubMed ID: 15224791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
    Molinuevo JL; Lladó A; Rami L
    Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications in Alzheimer's disease.
    Goñi-Oliver P; Avila J; Hernández F
    J Alzheimers Dis; 2009; 18(4):843-8. PubMed ID: 19661623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies on the interaction of NMDA receptor antagonist memantine with cell membranes: A mini-review.
    Zambrano P; Suwalsky M; Jemiola-Rzeminska M; Strzalka K
    Chem Biol Interact; 2018 Mar; 283():47-50. PubMed ID: 29407462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of moderate to severe Alzheimer's disease: focus on memantine.
    Dominguez E; Chin TY; Chen CP; Wu TY
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
    Song MS; Rauw G; Baker GB; Kar S
    Eur J Neurosci; 2008 Nov; 28(10):1989-2002. PubMed ID: 19046381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Memantine: from the original brand to generics].
    Titova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):136-143. PubMed ID: 29171502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
    Wenk GL
    J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?
    Doggrell S
    Expert Opin Pharmacother; 2003 Oct; 4(10):1857-60. PubMed ID: 14521495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Memantine: a therapeutic approach in treating Alzheimer's and vascular dementia.
    Koch HJ; Uyanik G; Fischer-Barnicol D
    Curr Drug Targets CNS Neurol Disord; 2005 Oct; 4(5):499-506. PubMed ID: 16266284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of action of memantine.
    Johnson JW; Kotermanski SE
    Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Memantine: Updating a rare success story in pro-cognitive therapeutics.
    Karimi Tari P; Parsons CG; Collingridge GL; Rammes G
    Neuropharmacology; 2024 Feb; 244():109737. PubMed ID: 37832633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors.
    Shi X; Lin X; Hu R; Sun N; Hao J; Gao C
    Am J Alzheimers Dis Other Demen; 2016 Aug; 31(5):405-12. PubMed ID: 26769920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Memantine: an antiglutamatergic option for dementia.
    Molinuevo JL; Garcia-Gil V; Villar A
    Am J Alzheimers Dis Other Demen; 2004; 19(1):10-8. PubMed ID: 15002339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.